Research · Sep 3, 2026
[IFF] International Flavors and Fragrances Thesis 2026: DuPont N&B Integration Tests Flavors and Fragrances Refocus
International Flavors & Fragrances Inc. (NYSE: IFF) FY2025 revenue ~$11-11.5B (-3 to 0%) with adj. EPS ~$1.10-2.00 reflecting continued post-2021 DuPont Nutrition & Biosciences (N&B) $26.2B integration challenges (~$2-3B+ FY2022-2024 goodwill impairments) + selected May 2025 Pharma Solutions $2.85B divestiture to Roquette (closed) + selected post-2023 dividend cut ~50% from $3 to $1.60 + selected new CEO Erik Fyrwald strategic reset (since February 2024). Leading global flavors + fragrances + specialty ingredients firm. Founded 1909 in New York as Polak's Frutal Works (~116-year heritage; selected initial focus on selected flavors + fragrances); selected various rebrands and acquisitions through history including 1958 IFF formation via merger of selected predecessor companies + 2018 Frutarom $7.1B acquisition + February 2021 DuPont Nutrition & Biosciences (N&B) $26.2B all-stock acquisition. Selected post-2021 transformative DuPont N&B merger created selected diversified specialty ingredients platform but with selected significant integration challenges + writedowns. Headquartered in New York New York; ~22,000+ employees globally with ~$11-11.5B revenue. Four reporting segments: Nourish ~50% revenue ($5.5B — Flavors + Functional Ingredients for food/beverage including post-2018 Frutarom + post-2021 DuPont N&B legacy; ~25-30% global flavors market share), Health & Biosciences ~20% ($2.2B — enzymes + cultures + probiotics post-2021 DuPont N&B legacy), Scent ~20% ($2.2B — fragrances for personal care + home care + fine fragrance), Pharma Solutions ~10% ($1.1B — pharmaceutical excipients; selected divestiture announced 2024 closed May 2025 ~$2.85B to Roquette). May 2025 Pharma Solutions divestiture: $2.85B all-cash sale to Roquette closed May 1, 2025; pure-play flavors + fragrances + biosciences focus post-divestiture; ~$2-3B debt reduction + operational simplification. DuPont N&B integration challenges: post-February 2021 $26.2B all-stock acquisition created diversified platform but with ~$10-11B+ debt assumed driving leverage stress + ~$2-3B+ FY2022-2024 goodwill impairments reflecting DuPont N&B underperformance vs acquisition assumptions + synergy shortfall vs original ~$300M target + post-2023 dividend cut from ~$3 to ~$1.60 (~50% reduction). CEO Erik Fyrwald since February 2024 (succeeded Frank Clyburn CEO February 2022-February 2024 retired who led post-DuPont N&B integration; Fyrwald ex-Syngenta CEO 2016-February 2024 + ex-Nalco/Ecolab CEO 2011-2016 + ~30-year specialty chemicals career; selected appointed to drive post-DuPont N&B refocus + operational reset). Capital return: ~$1.60-1.68 annual dividend FY2025 (post-2023 dividend cut from ~$3); modest buybacks $200-400M FY2025; investment-grade Baa3/BBB- credit ratings; FCF $0.5-0.8B; net debt $7-8B (post-Pharma Solutions divestiture). FY2026 thesis: post-Pharma divestiture refocus + DuPont N&B integration completion + operating margin expansion + capital return acceleration. Risks: DuPont N&B continued goodwill impairment, major Health & Biosciences customer attrition, Givaudan + Symrise competitive substitution, major Nourish market share loss.